{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T16:30:02Z","timestamp":1777566602471,"version":"3.51.4"},"reference-count":36,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2006,4,27]],"date-time":"2006-04-27T00:00:00Z","timestamp":1146096000000},"content-version":"vor","delay-in-days":5199,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin Experimental Allergy"],"published-print":{"date-parts":[[1992,2]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>To study the effect of azelastine on the immediate reaction to nasal allergen challenge, we performed a double blind, placebo\u2010controlled cross\u2010over clinical trial. Thirteen subjects with seasonal allergic rhinitis underwent nasal challenge with antigen 4 hr after a single oral 2 mg dose of azelastine. The response was monitored by counting the number of sneezes and by measuring the levels of histamine, prostaglandin D<jats:sub>2<\/jats:sub>, immunoreactive sulphidopeptide leukotrienes, kinins and TAME\u2010esterase activity in recovered nasal lavages. After a single dose of azelastine, there was a significant reduction in sneezing (10 <jats:italic>vs<\/jats:italic> 2, <jats:italic>P<\/jats:italic>= 0.01) and in the median levels of recovered TAME\u2010esterase activity (63.1 <jats:italic>vs<\/jats:italic> 17.5 c.p.m. \u00d7 10<jats:sup>\u20103<\/jats:sup>, <jats:italic>P<\/jats:italic>= 0.01), immunoreactive sulphidopeptide leukotrienes (7.5 <jats:italic>vs<\/jats:italic> 2.1 ng\/ml, <jats:italic>P<\/jats:italic>= 0.03) and kinins (1370 <jats:italic>vs<\/jats:italic> 251 pg\/ml, <jats:italic>P<\/jats:italic>= 0.03), with no significant reduction in the median levels of histamine (3.7 <jats:italic>vs<\/jats:italic> 1.2 ng\/ml, <jats:italic>P<\/jats:italic>= 0.2) and prostaglandin D<jats:sub>2<\/jats:sub> (70 <jats:italic>vs<\/jats:italic> 70 pg\/ml, <jats:italic>P<\/jats:italic>= 0.2) compared to placebo (numbers represent total increase over diluent challenge). These results suggest that azelastine does not inhibit mast cell activation but affects the consequences of released histamine, namely sneezing, increased vascular permeability and the generation of kinins. The results further suggest that other cells, in addition to mast cells, might be responsible for the generation of leukotrienes during the early allergic response, and that azelastine reduces their ability to generate this mediator or that inhibition of leukotriene release from mast cells occurs at lower drug concentrations.<\/jats:p>","DOI":"10.1111\/j.1365-2222.1992.tb03085.x","type":"journal-article","created":{"date-parts":[[2006,4,28]],"date-time":"2006-04-28T13:49:14Z","timestamp":1146232154000},"page":"289-295","source":"Crossref","is-referenced-by-count":58,"title":["The effect of azelastine on the early allergic response"],"prefix":"10.1111","volume":"22","author":[{"given":"M.\u2010H.","family":"SHIN","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"BAROODY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"PROUD","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"KAGEY\u2010SOBOTKA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. M.","family":"LICHTENSTEIN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. M.","family":"NACLERIO","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2006,4,27]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"149","article-title":"In vivo and in vitro H1 antagonist properties of azelastine","volume":"23","author":"Diamantis W","year":"1981","journal-title":"Pharmacologist"},{"key":"e_1_2_1_3_2","first-page":"152","article-title":"Antagonism of leukotrienes, calcium and other spasmogens by azelastine","volume":"26","author":"Chand N","year":"1984","journal-title":"Pharmacologist"},{"key":"e_1_2_1_4_2","first-page":"200","article-title":"Inhibition of release of SRS\u2010A and its antagonism by azelastine (A), an H1 antagonist\u2010antiallergic agent","volume":"24","author":"Diamantis W","year":"1982","journal-title":"Pharmacologist"},{"key":"e_1_2_1_5_2","first-page":"1184","article-title":"Pharmacological and toxicological properties of azelastine: a novel antiallergic agent","volume":"31","author":"Zechel HJ","year":"1981","journal-title":"Arzneim Forsch"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(84)90415-9"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(83)90311-4"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1159\/000233825"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02022975"},{"key":"e_1_2_1_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90096-1"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1986.tb10835.x"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-2952(84)90072-8"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(89)90125-5"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(87)90238-7"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(85)90385-9"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90082-6"},{"key":"e_1_2_1_17_2","first-page":"597","article-title":"Mediator release after nasal airway challenge with allergen","volume":"128","author":"Naclerio RM","year":"1983","journal-title":"Am Rev Respir Dis"},{"key":"e_1_2_1_18_2","first-page":"181","article-title":"The effects of autonomotropic drugs on allergic nasal mucosa","volume":"24","author":"Watase T","year":"1986","journal-title":"Rhinology"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/0003-2697(74)90093-1"},{"key":"e_1_2_1_20_2","first-page":"76","volume-title":"Chemistry and biology of the kallikrein\u2010kinin system in health and disease","author":"Imanari T","year":"1986"},{"key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4049\/jimmunol.137.3.977","article-title":"Plasma kallikrein during experimentally\u2010induced allergic rhinitis: role in kinin formation and contribution to TAME\u2010esterase activity in nasal secretions","volume":"137","author":"Baumgarten DR","year":"1986","journal-title":"J Immunol"},{"key":"e_1_2_1_22_2","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.4049\/jimmunol.137.4.1323","article-title":"Concentrations of glandular kallikrein in human nasal secretions during experimentally induced allergic rhinitis","volume":"137","author":"Baumgarten CR","year":"1986","journal-title":"J Immunol"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198406213102502"},{"key":"e_1_2_1_24_2","first-page":"441","article-title":"The effects of H1 and H2 antihistamines on \u2018allergic\u2019 histamine release and its inhibition by histamine","volume":"192","author":"Lichtenstein LM","year":"1975","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03370020071030"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/142.1.167"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1288\/00005537-198906000-00006"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(88)90058-9"},{"key":"e_1_2_1_29_2","first-page":"214","article-title":"Cetirizine blocks granulocyte influx into allergic late phase reaction sites [Abstract]","volume":"85","author":"Massey WA","year":"1990","journal-title":"J Allergy Clin Immunol"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(86)90233-2"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706113162403"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm\/137.3.613"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(86)90725-9"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1159\/000235420"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02028274"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000234309"},{"key":"e_1_2_1_37_2","first-page":"218","article-title":"Effects of a specific inhibitor of the 5\u2010lipoxygenase pathway on mediator release from human basophils and mast cells","volume":"247","author":"Warner JA","year":"1988","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Clinical &amp; Experimental Allergy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2222.1992.tb03085.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2222.1992.tb03085.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T12:39:02Z","timestamp":1698064742000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2222.1992.tb03085.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1992,2]]}},"alternative-id":["10.1111\/j.1365-2222.1992.tb03085.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2222.1992.tb03085.x","archive":["Portico"],"relation":{},"ISSN":["0954-7894","1365-2222"],"issn-type":[{"value":"0954-7894","type":"print"},{"value":"1365-2222","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,2]]}}}